Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR1459 in Primary Membranous Nephropathy
NCT05136456Phase 2Unknown
- Sponsor
- Reistone Biopharma
- Start
- Dec 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of edralbrutinib in primary membranous nephropathy (PMN), sponsored by Reistone Biopharma. Status: unknown.
02
Drugs
edralbrutinib
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT05136456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136456.